Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Galecto, Inc. (GLTO : NSDQ)
 
 • Company Description   
Galecto Inc. is a clinical stage biotechnology company with advanced programs in fibrosis and cancer centered on galectin-3 and LOXL2. The Company's pipeline includes an inhaled galectin-3 modulator currently in Phase 2b for the potential treatment of idiopathic pulmonary fibrosis. Galecto Inc. is headquarters in Copenhagen, Denmark.

Number of Employees: 40

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.39 Daily Weekly Monthly
20 Day Moving Average: 60,983 shares
Shares Outstanding: 25.26 (millions)
Market Capitalization: $35.11 (millions)
Beta: 1.22
52 Week High: $7.80
52 Week Low: $1.36
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -35.94% -29.81%
12 Week -26.06% -19.78%
Year To Date -54.13% -45.45%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
75 STATE STREET SUITE 100
-
BOSTON,MA 02109
DNK
ph: 45-7070-5210
fax: -
None http://www.galecto.com
 
 • General Corporate Information   
Officers
Hans T. Schambye - President; Chief Executive Officer and Director
Carl Goldfischer - Chairman
Jonathan Freve - Chief Financial Officer
Jayson Dallas - Director
Chau Q. Khuong - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 36322Q107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 25.26
Most Recent Split Date: (:1)
Beta: 1.22
Market Capitalization: $35.11 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.69 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.64 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.35
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -26.42%
vs. Previous Quarter: -26.42%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -45.22
12/31/21 - -38.28
09/30/21 - -33.90
ROA
03/31/22 - -43.08
12/31/21 - -36.73
09/30/21 - -32.58
Current Ratio
03/31/22 - 13.45
12/31/21 - 24.23
09/30/21 - 18.63
Quick Ratio
03/31/22 - 13.45
12/31/21 - 24.23
09/30/21 - 18.63
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 4.01
12/31/21 - 4.64
09/30/21 - 5.13
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©